Welcome

to

the

future

of

neurotherapeutics.

Our Mission

Around the world, millions are losing memories, identities, and futures to brain diseases we still cannot stop. It is a crisis advancing more rapidly than scientific progress can currently match.

But, the past does not have to define our future.

Sculpta is forging a bold new path with the development of  Protein SculptingTM  drugs, powered by cutting edge technology, scientific excellence, and a relentless spirit of urgency. Humanity cannot wait any longer.

Discover how we are challenging the status quo by reshaping the future of brain health.

Our Platform

ADVANCED NEURAL TISSUE ANALYSIS

Quality over quantity

Single cell genomics has revolutionized biological discovery, yet quality is often sacrificed for quantity. The most widely used platforms capture only the very ends of transcripts. AI models trained on this inaccurate data are not capturing disease-associated changes.

Sculpta’s platform captures full-length transcripts, powering our ATLAS AI-platform that is driving unique insights into the neurobiology of human disease.

ACCURATE PRE-CLINICAL MODELS

Human models for human disease

The associations between human nucleotide variants and disease are critical for the discovery of new targets. We are mining non-coding human variants and interpreting findings with our functional transcriptomics data to lead new target discovery in Alzheimer’s, Parkinson’s, neurodevelopment, and amyotrophic lateral sclerosis.

Instead of turning to mouse models, we use human stem cell derived models called organoids to accurately study disease pathophysiology.

A BOLD, NEW APPROACH

Protein Sculpting Therapeutics

Other companies try to drug proteins in the brain to treat disease. We change them.

Sculpta is the pioneer in Protein SculptingTM therapeutics, drugs that change the structure and function of disease-causing proteins in the brain using programmable RNA medicines.

We move beyond “up/down” genomic medicines, offering safer, more specific, and more effective therapies for devastating brain disorders, brought to patients faster.

Team

Neal Amin, MD, PhD

Founder | CEO

Mislav Acman

Senior Computational Biologist

Amina Khan, PhD

Research Associate

Bryan van Nimwegen, PhD

Computational Biologist

Joshua Berlind

Scientist

Joshua Berlind

Scientist

Neal Amin

Founder | CEO

Mislav Acman

Senior Computational Biologist

Amina Khan

Research Associate

Bryan van Nimwegen

Computational Biologist

Joshua Berlind

Scientist

Investors

News

March 2025

New Publication in Neuron

Research led by Sculpta scientist Joshua Berlind discovers excitotoxicity pathway in tau-opathies using advanced human brain organoid technology.
March 2025

Sculpta Closes $2.6M Funding Round

Sculpta has successfully secured $2.6M in pre-seed funding from six venture capital groups and six angels to accelerate the the development of protein sculpting therapies for devastating brain disorders.

April 2025

New Publication in Nature

Groundbreaking work on modeling human neurosensation for drug development with contributions from Sculpta CEO and Founder Neal Amin.
April 2025

New Publication in Nature

Neal Amin, CEO

Groundbreaking work on modeling human neurosensation for drug development with contributions from Sculpta CEO and Founder Neal Amin.

March 2025

Sculpta Closes $2.6M Funding Round

Sculpta has successfully secured $2.6M in pre-seed funding from six venture capital groups and six angels to accelerate the the development of protein sculpting therapies for devastating brain disorders.

March 2025

New Publication in Neuron

Joshua Berlind, Scientist

Research led by Sculpta scientist Joshua Berlind discovers excitotoxicity pathway in tau-opathies using advanced human brain organoid technology.

Scroll to Top